During 2018 Q4 the big money sentiment decreased to 0.94. That’s change of 0.81, from 2018Q3’s 1.75. 61 investors sold all, 89 reduced holdings as Nektar Therapeutics ratio is negative. 101 grew holdings while 40 funds took holdings. Funds hold 160.47 million shares thus 4.08% more from 2018Q3’s 154.18 million shares.
Franklin Street Advsr Inc Nc reported 28,000 shs. Natixis has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Rice Hall James & Assoc Ltd Liability stated it has 0.78% of its capital in Nektar Therapeutics (NASDAQ:NKTR). New Mexico Educational Retirement Board has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Aqr holds 0.04% of its capital in Nektar Therapeutics (NASDAQ:NKTR) for 1.08 million shs. Proshare Advsr Ltd Liability Corporation has invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR). Bb&T Secs reported 0% in Nektar Therapeutics (NASDAQ:NKTR). Balyasny Asset Management Ltd Llc owns 99,794 shs or 0.02% of their US capital. Tower Research Limited Liability (Trc) holds 4,186 shs. Tarbox Family Office owns 9 shs. Daiwa Inc invested in 7,294 shs. Group Inc One Trading Lp owns 0.02% invested in Nektar Therapeutics (NASDAQ:NKTR) for 71,295 shs. Gulf Intl National Bank & Trust (Uk) holds 0.03% in Nektar Therapeutics (NASDAQ:NKTR) or 38,639 shs. The Massachusetts-based Westfield Mgmt L P has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Mason Street Advsrs Limited Company accumulated 24,402 shs.

Nektar Therapeutics had 8 selling transactions and 0 insider purchases since November 16, 2018. This’s net activity of $4.95 million. On Friday, November 16 the insider Nicholson John sold $228,812. Shares for $173,043 were sold by Doberstein Stephen K. Another trade for 6,515 shs valued at $249,199 was sold by Labrucherie Gil M. Hora Maninder had sold 4,694 shs worth $179,546 on Friday, November 16. On Friday, November 16 a trade for 15,326 shs valued at $586,220 was made by ROBIN HOWARD W.

Nektar Therapeutics (NASDAQ:NKTR) reported a decrease of 3.32% in short interest. In April was announced NKTR’s total 19.26 million short interest by FINRA. That’s 3.32% down from 19.92M shares. Nektar Therapeutics (NASDAQ:NKTR) has 1.66M shares average volume. It’ll cost 12 days for NKTR to recover its previous position.

NKTR is touching $31.19 during the last trading session, after decreased 6.56%.Nektar Therapeutics has 2.01M shares volume, 26.75% up from normal. NKTR is downtrending and has moved 54.70% since April 18, 2018. NKTR underperformed the S&P500 by 59.07%.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States.The company has $5.43 billion market cap. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain.8.25 is the P/E ratio. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

A total of 7 analysts rate Nektar Therapeutics (NASDAQ:NKTR) as follows: 6 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 86% are bullish. The firm has $100 highest and $47 lowest target. The avg target $74.86 is 140.01% above the last ($31.19) price. (NASDAQ:NKTR) has 10 ratings reports on Apr 18, 2019 according to StockzIntelligence. On Tuesday, November 13 the firm has “Buy” rating by Canaccord Genuity given. On Friday, March 1 the firm earned “Buy” rating by Mizuho. On Thursday, November 8 the firm earned “Buy” rating by Jefferies. On Friday, March 1 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, February 19 the company was maintained by H.C. Wainwright. On Tuesday, February 19 the rating was maintained by Mizuho with “Buy”. On Monday, March 4 H.C. Wainwright maintained the shares of NKTR in report with “Hold” rating.

For more Nektar Therapeutics (NASDAQ:NKTR) news brought out recently go to: Benzinga.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial – Benzinga” brought out on April 02, 2019, “FDA’s Gottlieb proposes higher standard for future opioid approvals – Seeking Alpha” on March 28, 2019, “Key events next week – healthcare – Seeking Alpha” with a publish date: March 22, 2019, “Nektar Therapeutics Q4 2018 Earnings Preview – Seeking Alpha” and the last “Nektar -5.9% as it reports urothelial cancer study – Seeking Alpha” with publication date: February 11, 2019.